Efficacy of Nerve Blocks for Episodic Migraine

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2026

Conditions
Episodic Migraine
Interventions
DRUG

Bupivacaine HCl 0.5% Injectable Solution

Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.

DRUG

Methylprednisolone 40 MG Injection

Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05734625 - Efficacy of Nerve Blocks for Episodic Migraine | Biotech Hunter | Biotech Hunter